Press release
United States Chemotherapy-Induced Peripheral Neuropathy (CIPN) Treatment Market to Reach USD 1.45 Billion by 2034
United States Chemotherapy-Induced Peripheral Neuropathy (CIPN) Treatment
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/48143
Key Takeaways
• Market Size (2024): USD 830 Million
• Forecast (2034): USD 1.45 Billion
• CAGR (2025-2034): 5.7 %
• Key Segments: Drug Class, Therapy Type, Distribution Channel, and End User
• Leading Companies: Eli Lilly and Company, Pfizer Inc., Novartis AG, Amgen Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., and Nevro Corp.
Market Story
Chemotherapy-Induced Peripheral Neuropathy (CIPN) affects nearly 40-60 % of cancer patients, causing chronic pain, tingling, and sensory loss. As oncology survival rates improve, clinicians and researchers are prioritizing neuroprotective and symptomatic-relief therapies to preserve long-term function.
Pharmaceutical pipelines are advancing serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, and novel calcium-channel blockers, while medical-device innovators focus on neurostimulation, cryotherapy, and wearable pain-relief systems. AI-enabled symptom-tracking platforms integrated with electronic health records are emerging as critical tools for personalized neuropathy management in oncology centers across the U.S.
Market Segmentation
By Drug Class: Antidepressants (SNRIs, TCAs), Anticonvulsants, Opioids, Topical Analgesics, Others
By Therapy Type: Pharmacological, Physical Therapy, Neuromodulation, Cryotherapy, Acupuncture, Integrative Medicine
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By End User: Hospitals & Cancer Institutes, Specialty Pain Clinics, Home-Care Settings
Explore Full Report here: https://exactitudeconsultancy.com/reports/48143/united-states-chemotherapy-induced-peripheral-neuropathy-treatment-market
Recent Developments
• Pfizer Inc. initiated trials evaluating Duloxetine in combination with neuroprotective adjuvants for enhanced CIPN pain control.
• Nevro Corp. expanded its FDA-approved HFXTM spinal-cord-stimulation system to include oncology-related neuropathic pain indications.
• Amgen Inc. invested in pre-clinical studies of small-molecule neuro-regeneration agents targeting axonal repair.
• Astellas Pharma partnered with U.S. research institutes for Phase II evaluation of novel sodium-channel inhibitors for CIPN.
• Teva Pharmaceuticals introduced affordable generic formulations of gabapentinoids to expand patient access.
Expert Insight
"CIPN management is moving from reactive pain control to proactive nerve-protection strategies. Combination therapies and digital symptom monitoring are becoming the new standards in personalized oncology support,"
- Lead Analyst, Exactitude Consultancy
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=48143
Market Drivers
• Rising Cancer Prevalence: Over 1.9 million new cancer cases expected annually in the U.S.
• Innovation in Neuromodulation: Growing use of spinal-cord stimulators and non-invasive nerve-stimulation wearables.
• Patient-Centric Oncology: Emphasis on quality-of-life metrics within value-based care frameworks.
• Clinical-Trial Pipeline Growth: Increased R&D into neuroprotective drugs and regenerative compounds.
Forecast & Regional Insights
The United States leads global CIPN research and commercialization, accounting for nearly 45 % of worldwide market revenue (2024). High clinical-trial density, strong reimbursement infrastructure, and collaboration among academic hospitals, biotech firms, and pain-management centers sustain market momentum. Urban oncology hubs-particularly in California, Massachusetts, and Texas-are driving adoption of advanced digital-therapeutic and neuromodulation solutions.
Conclusion
The U.S. CIPN Treatment Market underscores the evolving landscape of supportive oncology care, where technology, pharmacology, and patient-centric approaches converge. As innovation accelerates in neuroprotection and rehabilitation, CIPN management is poised to become a defining pillar of comprehensive cancer recovery.
This report is also available in the following languages : Japanese (米国における化学療法誘発性末梢神経障害の治療), Korean (미국 화학요법 유발 말초신경병증 치료), Chinese (美国化疗诱发周围神经病变治疗), French (Traitement de la neuropathie périphérique induite par la chimiothérapie aux États-Unis), German (Behandlung der durch Chemotherapie verursachten peripheren Neuropathie in den Vereinigten Staaten), and Italian (Trattamento della neuropatia periferica indotta dalla chemioterapia negli Stati Uniti), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/48143/united-states-chemotherapy-induced-peripheral-neuropathy-treatment-market#request-a-sample
Related Reports
Chronic Pain associated with Painful Diabetic Neuropathy Market
https://exactitudeconsultancy.com/reports/70787/chronic-pain-associated-with-painful-diabetic-neuropathy-market
Chronic Neuropathic Pain Market
https://exactitudeconsultancy.com/reports/70792/chronic-neuropathic-pain-market
Chronic Pain associated with Painful Diabetic Neuropathy Market
https://exactitudeconsultancy.com/reports/70846/chronic-pain-associated-with-painful-diabetic-neuropathy-market
Sensory Neuropathy Market
https://exactitudeconsultancy.com/reports/71050/sensory-neuropathy-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Chemotherapy-Induced Peripheral Neuropathy (CIPN) Treatment Market to Reach USD 1.45 Billion by 2034 here
News-ID: 4259299 • Views: …
More Releases from Exactitude Consultancy
Fetal Monitoring System Market to Reach USD 8.5 Billion by 2034
Introduction
Pune, India - November 2025 - Exactitude Consultancy, a leading global market research and consulting firm, has published its latest study on the Global Fetal Monitoring System Market, forecasting sustained growth driven by rising global birth rates, increasing awareness about prenatal health, and the integration of smart technologies in fetal and maternal monitoring systems.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/75977
Key Takeaways
• The fetal monitoring system market was valued…
Alzheimer's Disease Treatment Market to Surpass USD 22.4 Billion by 2034
Introduction
Pune, India - November 2025 - Exactitude Consultancy has announced the release of its latest study on the Global Alzheimer's Disease Treatment Market, providing an in-depth analysis of market dynamics, therapeutic innovations, and strategic investments shaping the future of neurodegenerative healthcare. The report forecasts substantial growth through 2034 as the world continues to battle rising dementia cases and invests in early-stage detection and advanced biologic therapies.
Download Full PDF Sample Copy…
Chemical Intermediate Market to Reach USD 792.3 Billion by 2034
Introduction
Pune, India - November 2025 - Exactitude Consultancy, a global market intelligence and research firm, has published its latest study on the Global Chemical Intermediate Market, revealing promising growth prospects through 2034. The report attributes this expansion to the increasing use of intermediates in pharmaceuticals, polymers, dyes, coatings, and agrochemicals, alongside a rapid transition toward sustainable and bio-based production processes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/76111
Key Takeaways
• The…
Telepsychiatry Market to Reach New Heights by 2034 Driven by Rising Mental Healt …
Introduction
Pune, India - November 2025 - Exactitude Consultancy has released its latest study on the Global Telepsychiatry Market, revealing strong and sustained growth through 2034. The report highlights how advancements in digital health infrastructure, the growing global mental health crisis, and increased government support for telemedicine are propelling the telepsychiatry industry toward unprecedented expansion.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/75907
Key Takeaways
• The global telepsychiatry market is valued at…
More Releases for CIPN
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Growing Focus and Marke …
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side effect of cancer treatment, caused by damage to peripheral nerves from drugs such as platinum compounds, taxanes, vinca alkaloids, and proteasome inhibitors. CIPN manifests as pain, numbness, tingling, and motor dysfunction, often leading to dose reduction or discontinuation of chemotherapy, which can compromise cancer outcomes.
With up to 68% of patients developing CIPN during chemotherapy, this condition represents a significant unmet…
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline 2025: Groundbreaking …
With Chemotherapy Induced Peripheral Neuropathy (CIPN) reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline comprises 4+ pharmaceutical and biotech companies actively developing 5+ therapeutic candidates targeting Chemotherapy Induced Peripheral Neuropathy (CIPN). These therapies span various stages of clinical and…
Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market 2034: Clinica …
Chemotherapy Induced Peripheral Neuropathy companies working in the market are Egetis Therapeutics, MediciNova, Sonnet Biotherapeutics, MakScientific, MediciNova, Asahi Kasei Pharma Corp., AnnJi Pharmaceutical, EA Pharma, Aptinyx, Sonnet Biotherapeutics Holdings, Toray, Solasia Pharma, Enveric Biosciences, Regenacy Pharmaceuticals, NeuroBo Pharmaceuticals and others.
(Albany, USA) DelveInsight's "Chemotherapy Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Chemotherapy Induced Peripheral Neuropathy, historical and forecasted epidemiology as well as the…
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Set to Experience Unpre …
DelveInsight's "Chemotherapy-Induced Peripheral Neuropathy (CIPN) Patient Pool Analysis, Market Size and Market Forecast APAC, 2034" report delivers an in-depth understanding of Chemotherapy-Induced Peripheral Neuropathy (CIPN), historical and forecasted epidemiology as well as the Chemotherapy-Induced Peripheral Neuropathy (CIPN) market trends in the India, China, South Korea, Taiwan, and Australia.
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the…
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Analysis Covering Cli …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy Induced Peripheral Neuropathy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chemotherapy Induced Peripheral Neuropathy…
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Analysis (2023) Cover …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 13+ key pharma and biotech companies are working on 13+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy (CIPN) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chemotherapy-Induced Peripheral Neuropathy (CIPN)…
